Will expensive Hep C drug, Sovaldi, really save the system money? Who should get it?

By Prue Salasky

The controversy around Sovaldi, the new drug proven to cure Hep C in more than 90 percent of patients, continues to swirl. By itself, its cost threatens to drive up Medicare drug costs by several percentage points annually. The government has recommended that all baby-boomers get tested for Hep C -- about 3 million are expected to test positive.

Here's one take on the problem of whether it's a savings, and by extension, how much a person's life is worth ... If we have a cure, shouldn't it be used regardless? Check out this story in Modern Healthcare: